These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12690409)

  • 41. Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder.
    Campbell IH; Campbell H; Smith DJ
    Transl Psychiatry; 2022 Aug; 12(1):350. PubMed ID: 36038539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of cellular and synaptic variability in the lamprey spinal cord.
    Parker D; Bevan S
    J Neurophysiol; 2007 Jan; 97(1):44-56. PubMed ID: 17021027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of bipolar disorder: new perspectives.
    Alda M; Hajek T; Calkin C; O'Donovan C
    Ann Med; 2009; 41(3):186-96. PubMed ID: 18821183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder.
    McQuillin A; Rizig M; Gurling HM
    Pharmacogenet Genomics; 2007 Aug; 17(8):605-17. PubMed ID: 17622937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Looking at lithium: molecular moods and complex behaviour.
    Beaulieu JM; Caron MG
    Mol Interv; 2008 Oct; 8(5):230-41. PubMed ID: 19015387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lithium neuroprotection: molecular mechanisms and clinical implications.
    Rowe MK; Chuang DM
    Expert Rev Mol Med; 2004 Oct; 6(21):1-18. PubMed ID: 15488156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders.
    Bauer M; Alda M; Priller J; Young LT;
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S250-4. PubMed ID: 14677087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does lithium save lives?
    Joffe RT
    J Psychiatry Neurosci; 2004 Jan; 29(1):9-10. PubMed ID: 14719045
    [No Abstract]   [Full Text] [Related]  

  • 50. Lithium mechanisms in bipolar illness and altered intracellular calcium functions.
    Meltzer HL
    Biol Psychiatry; 1986 May; 21(5-6):492-510. PubMed ID: 2421787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium.
    Aghdam SY; Barger SW
    Curr Alzheimer Res; 2007 Feb; 4(1):21-31. PubMed ID: 17316163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular studies probe bipolar disorder.
    Friedrich MJ
    JAMA; 2005 Feb; 293(5):535-6. PubMed ID: 15687298
    [No Abstract]   [Full Text] [Related]  

  • 53. Akt/GSK3 signaling in the action of psychotropic drugs.
    Beaulieu JM; Gainetdinov RR; Caron MG
    Annu Rev Pharmacol Toxicol; 2009; 49():327-47. PubMed ID: 18928402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Predictors of prophylactic response to lithium].
    Rohayem J; Baylé JF; Richa S
    Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium.
    Ghasemi M; Dehpour AR
    Trends Pharmacol Sci; 2011 Jul; 32(7):420-34. PubMed ID: 21492946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo.
    Chen G; Masana MI; Manji HK
    Bipolar Disord; 2000 Sep; 2(3 Pt 2):217-36. PubMed ID: 11249800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuropeptide y in euthymic lithium-treated women with bipolar disorder.
    El Khoury A; Mathé AA
    Neuropsychobiology; 2004; 50(3):239-43. PubMed ID: 15365223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interrelations between lithium therapy, auto-immune thyroiditis and TSH. A case report.
    Mouaffak F; Gourevitch R; Baup N; Lôo H; Olié JP
    Pharmacopsychiatry; 2006 Mar; 39(2):77-8. PubMed ID: 16555169
    [No Abstract]   [Full Text] [Related]  

  • 60. Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy.
    Damri O; Shemesh N; Agam G
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.